Nasdaq Falls as Oil Prices Surge Ahead of Bank Earnings 
Bumble Shares Surge 50% on $1 Billion Buyout Talks 
Deutsche Bank CEO Urges Faster German Economic Reforms 
Nvidia’s China AI Chip Market Share Falls to 34% as Huawei Gains Ground 
Most Americans Oppose Election Betting on Prediction Markets, Poll Finds 
Samsung, SK Hynix Shares Fall as China's CXMT Advances DRAM Technology 
FAA Warns US Airlines Over Saudi Arabia Flight Risks 
IMF, World Bank Meetings Face Global Economic Risks Amid Iran War 
Moonshot AI Executives Seek Settlement Ahead of Hong Kong IPO 
Apple Supplier Luxshare Faces US Patent Probe, Sees Limited Impact 
Canton Network Expands in South Korea With Major Partnerships 
Airbus Tests Valkyrie Combat Drone in Europe for Eurofighter Integration 
European Auto Stocks Rise as EU-China Trade Deal Targets Hybrid Imports 
S&P 500 Rally Masks Losses for Over 40% of Stocks in 2026 
Oil Prices Fall as Trump Ceasefire Claim Shifts Market Focus to U.S. CPI 
Samsung, SK Hynix Shares Plunge as China Chip Competition Grows 
Gold Prices Rise Above $4,200 as Russia-Ukraine Energy Truce Eases Oil Concerns 
Add as a preferred source on Google
Celltrion, the South Korean pharmaceutical company, revealed that it had sealed its first deal for shipments of its Rekirona COVID-19 antibody treatment. The firm made the announcement on the supply transaction to Pakistan on Monday, May 10.
Celltrion’s Healthcare division will be managing its overseas business, so it was the company affiliate that signed the deal with Pakistan’s state-run company. The first order is for the shipment of 100,000 vials of Rekirona, which is enough for 30,000 people.
Rekirona receives approval from S. Korea’s drug safety board
As per The Korea Herald, once the vials of the COVID-19 antibody treatment have been delivered, Celltrion will also send its experts to Pakistan so they can train the local medical healthcare providers who have been assigned to administer the treatment.
In February, Celltrion’s Rekirona already received conditional approval from the drug safety board in S. Korea. With that, the medication effectively became the first locally-made treatment for coronavirus.
The treatment has been given to around 2,700 high-risk patients, which include individuals who are over 60 years of age. People with chronic diseases that affect the respiratory system were also administered with Rekirona earlier this year, and the results seem promising, or it will not be approved.
Celltrion already completed the third phase of clinical trials that was conducted in 13 countries with 1,300 volunteers. Aside from S. Korea, some of these nations are the U.S. and Spain. Now, the pharma company is hoping that its Rekirona will be able to help stop the growing number of patients in Pakistan.
Celltrion starts global rollout of its COVID-19 treatment
Yonhap News Agency reported that it is not just Pakistan that will have Celltrion’s Rekirona as there are also ongoing negotiations for supply to Europe, U.S., and more. The exports will start in Pakistan, and the distribution will eventually spread to other nations.
"Talks are also currently underway to export Rekirona to other countries in Europe and South America, as well as India," an official from Celltrion said. Meanwhile, two other pharmaceutical companies are developing similar monoclonal antibody treatment, and these are the US-based Regeneron and Eli Lilly. These are still under clinical tests, so it makes Celltrion the first to make a COVID-19 treatment available globally.
